Retour aux projets

12803.1;11 VOUCH-LS

Innovative 'armed' antibodies

Résumé

Innovative 'armed' antibodies

Textes supplémentaires

Abstract

Monoclonal antibodies represent the largest and fastest growing class of biotechnology products. While conventional antibody products are based on intact IgG, there is a growing trend towards ¿arming¿ antibodies with therapeutic payloads. The Philogen group is one of the pioneers in the engineering of armed human antibodies for therapeutic applications. In order to retain and consolidate its leadership in the field, we need to stay ahead of competition and explore innovative immunocytokines, alongside with their possible clinical application areas.

Participants

Dario Neri

Kontaktperson

dario.neri@pharma.ethz.ch

ETH Zürich Inst. of Pharmac. Sciences Dario Neri Wolfgang-Paulistrasse 10 HCI G496 8093 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2012-03-31
Date de fin
2015-11-11
Coûts totaux approuvés
CHF 347744.00
Section
5 KTI
Domaine politique NABS
Nicht aufteilbare / nicht zuteilbare Forschung

Disciplines de recherche

  • T490 Biotechnology 100.0%